OMICS Group consists of Open Access Scholarly Journals and OMICS group conferences. Through its Scholarly Open Access Initiative is committed to make genuine and trustworthy contributions to the people who are doing research in the respective fields. OMICS Group hosts over 700+ peer-reviewed journals and organize over 3000+ International Scientific Conferences annually all over the world. OMICS International journals have over 15 million readers and the reputation and success of the same can be attributed to the strong editorial board which contains over 50,000+ editorial board members that ensure a rapid, quality and quick review process.
The term "malignancy" refers to cancerous cells that have the ability to spread to other sites in the body (metastasize) or to invade and destroy tissues. Malignant cells tend to have fast, uncontrolled growth due to changes in their genetic makeup. Malignant cells that are resistant to treatment may return after all detectable traces of them have been removed or destroyed. In medical school, future physicians are taught the phrase "primum non nocere", first do no harm. That adage motivates every physician, every healthcare provider, to go to great lengths to avoid an incorrect diagnosis for a patient. As a gynecological surgeon, that adage is put to the test with every operative patient dealing with a pelvic mass. Encountering an undiagnosed malignancy during and anticipated benign surgical intervention is stressful for the surgeon, but devastating to the unprepared patient. Recently, attention has focused on uterine morcellation at time of laparoscopic hysterectomy. Stemming from the inadvertent morcellation of a leiomyosarcoma in a patient presumed to have been benign fibroids, the question has arisen of informed consent disclosures versus the appropriateness of a selected surgery when the possibility of a malignancy exists.
Last date updated on September, 2020